August 2020 – The publication describes the FDA’s regulatory path for approving new Sotalol IV dosing for a 1-day initiation or dose escalation. The data shows how a 1-hour Sotalol IV infusion can quickly reach therapeutic levels and thus, reduce hospital length of stay from 3 days down to 1 day.
CHICAGO, March 10, 2020 -- AltaThera Pharmaceuticals, LLC, a hospital specialty pharmaceutical company focused on commercializing innovative drugs aimed at improving outcomes and reducing hospital costs, announces that the US Food and Drug Administration (FDA) has approved new indications for Sotalol IV in AFib patients. "The new indications for Sotalol IV represent a significant advance that decreases length of stay for new patients starting sotalol for AFib," said Jodi Devlin, AltaThera's CEO. "We are proud to continue our leadership in cardiac and critical care medicine as we work diligently to bring innovative therapies to patients in the United States. We are on target with our commercial launch preparations and expect to launch Sotalol IV's new indications in the second half of the year."
May 2019 – Boston Strategic Group and AltaThera present hospital cost savings by using a 1-day initiation regimen. Over 7,200 patients in the Cerner electronic health record system who were admitted to the hospital for initiation of oral sotalol were analyzed. By reducing 3-day sotalol initiation to a 1-day procedure, the cost-saving per patient is $3,000; a significant reduction in hospital costs.
Chicago, IL – 03/28/19 AltaThera Pharmaceuticals has recently partnered with Rush University Medical Center to support arrhythmia research around the world. Through a charitable donation of the medication IV Sotalol (sotalol hydrochloride injection 15mg/mL for intravenous use), AltaThera is supporting important research regarding prophylaxis for post-op dysrhythmias. The research is scheduled to take place at Hanoi Heart Hospital in Hanoi, Vietnam over the course of 2019/2020.
Chicago, IL – January 2019 – AltaThera has donated vials of IV sotalol to the Veterinary Program at the University of Pennsylvania to better understand heart arrhythmias in dogs.
As stated by Professor Anna Gelzer, PhD, Doctor of Veterinary Medicine, “Boxers are at an increased risk of arrhythmogenic right ventricular cardiomyopathy (ARVC), an inherited disease of the heart muscle. We are interested to test [IV sotalol’s] ability to suppress arrhythmia inducibility during an electrophysiologic study.”
AltaThera remains committed to research in all areas of cardiac arrhythmia and is excited about Dr. Gelzer’s clinical program.”